Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome.

S Husain, M M Wagener, N Singh
Author Information
  1. S Husain: Veterans Affairs Medical Center and University of Pittsburgh, Thomas E. Starzl Transplantation Institute, Pittsburgh, Pennsylvania 15240, USA.

Abstract

Unique clinical characteristics and other variables influencing the outcome of Cryptococcus neoformans infection in organ transplant recipients have not been well defined. From a review of published reports, we found that C. neoformans infection was documented in 2.8% of organ transplant recipients (overall death rate 42%). The type of primary immunosuppressive agent used in transplantation influenced the predominant clinical manifestation of cryptococcosis. patients receiving tacrolimus were significantly less likely to have central nervous system involvement (78% versus 11%, p =0.001) and more likely to have skin, soft-tissue, and osteoarticular involvement (66% versus 21%, p = 0.006) than patients receiving nontacrolimus- based immunosuppression. Renal failure at admission was the only independently significant predictor of death in these patients (odds ratio 16.4, 95% CI 1.9-143, p = 0.004). Hypotheses based on these data may elucidate the pathogenesis and may ultimately guide the management of C. neoformans infection in organ transplant recipients.

References

  1. Br Med J. 1971 Apr 10;2(5753):107 [PMID: 4927910]
  2. Transplantation. 1971 Apr;11(4):428-9 [PMID: 4934356]
  3. Transplant Proc. 1973 Mar;5(1):549-53 [PMID: 4572114]
  4. Arch Intern Med. 1975 Sep;135(9):1163-72 [PMID: 1100007]
  5. Surgery. 1976 Mar;79(3):268-77 [PMID: 769213]
  6. Arch Intern Med. 1976 Jun;136(6):670-7 [PMID: 776110]
  7. Brain. 1976 Dec;99(4):673-94 [PMID: 192413]
  8. Pathology. 1998 Aug;30(3):316-7 [PMID: 9770201]
  9. Infection. 1998 Sep-Oct;26(5):314-6 [PMID: 9795795]
  10. Medicine (Baltimore). 1999 Mar;78(2):123-38 [PMID: 10195093]
  11. Infect Immun. 1999 May;67(5):2218-24 [PMID: 10225877]
  12. Mol Cell Biol. 1999 Jun;19(6):4101-12 [PMID: 10330150]
  13. J Clin Microbiol. 1999 Oct;37(10):3204-9 [PMID: 10488178]
  14. Am J Clin Pathol. 1954 Dec;24(12):1381-90 [PMID: 13228372]
  15. J Urol. 1981 Feb;125(2):241-2 [PMID: 7009889]
  16. Ann Neurol. 1981 Feb;9(2):107-19 [PMID: 7015992]
  17. Infect Immun. 1981 Jun;32(3):1073-8 [PMID: 7251157]
  18. South Med J. 1981 Aug;74(8):1032-3 [PMID: 7022667]
  19. South Med J. 1981 Sep;74(9):1150-3 [PMID: 7025237]
  20. Proc Clin Dial Transplant Forum. 1976 Nov 19-22;6:13-9 [PMID: 801056]
  21. Jpn Circ J. 1977 Sep;41(9):1009-13 [PMID: 335102]
  22. Arch Intern Med. 1981 Jan;141(1):128-30 [PMID: 7004368]
  23. J Am Acad Dermatol. 1987 Sep;17(3):469-72 [PMID: 3308982]
  24. Neth J Med. 1987 Oct;31(3-4):183-90 [PMID: 3317088]
  25. Hautarzt. 1989 Jan;40(1):31-3 [PMID: 2537804]
  26. Infect Dis Clin North Am. 1989 Mar;3(1):77-102 [PMID: 2647836]
  27. N Engl J Med. 1989 Sep 21;321(12):794-9 [PMID: 2671735]
  28. Transplantation. 1989 Oct;48(4):692-5 [PMID: 2552628]
  29. South Med J. 1989 Dec;82(12):1555-6 [PMID: 2688133]
  30. J Thorac Imaging. 1990 Apr;5(2):84-6 [PMID: 2325190]
  31. Clin Chest Med. 1990 Jun;11(2):291-308 [PMID: 2189664]
  32. N Engl J Med. 1992 Jan 9;326(2):83-9 [PMID: 1727236]
  33. Clin Infect Dis. 1992 Mar;14(3):666-72 [PMID: 1562658]
  34. Transplant Proc. 1992 Oct;24(5):1898-9 [PMID: 1412904]
  35. Transplant Proc. 1992 Oct;24(5):1940-2 [PMID: 1412918]
  36. N Engl J Med. 1993 Jul 15;329(3):203-4 [PMID: 8390616]
  37. Nephron. 1993;65(4):646 [PMID: 8302429]
  38. J Am Acad Dermatol. 1994 Jun;30(6):1025-6 [PMID: 8188868]
  39. Transplantation. 1994 Oct 15;58(7):855-6 [PMID: 7940723]
  40. Clin Transplant. 1994 Aug;8(4):365-8 [PMID: 7949540]
  41. Scand J Infect Dis. 1994;26(5):623-6 [PMID: 7855562]
  42. Transplant Proc. 1995 Apr;27(2):1732 [PMID: 7725475]
  43. EMBO J. 1995 Jun 15;14(12):2772-83 [PMID: 7540976]
  44. J Biol Chem. 1995 Nov 17;270(46):27531-7 [PMID: 7499212]
  45. Antimicrob Agents Chemother. 1995 Nov;39(11):2588-90 [PMID: 8585754]
  46. Transplantation. 1996 Jan 15;61(1):146-9 [PMID: 8560554]
  47. Medicine (Baltimore). 1996 May;75(3):142-56 [PMID: 8965683]
  48. Clin Infect Dis. 1996 Jul;23(1):91-6 [PMID: 8816135]
  49. J Am Coll Surg. 1996 Oct;183(4):307-16 [PMID: 8843258]
  50. J Infect. 1996 Sep;33(2):95-101 [PMID: 8889996]
  51. Transplant Proc. 1996 Oct;28(5):2761-2 [PMID: 8908045]
  52. Antimicrob Agents Chemother. 1997 Jan;41(1):156-61 [PMID: 8980772]
  53. Clin Transplant. 1997 Feb;11(1):66-70 [PMID: 9067698]
  54. Ann Plast Surg. 1998 Jan;40(1):80-3 [PMID: 9464704]
  55. Retina. 1998;18(3):273-6 [PMID: 9654421]
  56. South Med J. 1981 Oct;74(10):1290 [PMID: 7027451]
  57. Ann Surg. 1982 Jan;195(1):104-9 [PMID: 7034656]
  58. Transplantation. 1981 Oct;32(4):334-6 [PMID: 7036449]
  59. Neuropatol Pol. 1982;20(3-4):495-503 [PMID: 6763975]
  60. Arch Intern Med. 1984 Sep;144(9):1877-8 [PMID: 6383247]
  61. Ann Intern Med. 1986 Feb;104(2):234-40 [PMID: 3946951]
  62. J Clin Microbiol. 1986 Nov;24(5):860-2 [PMID: 3533989]
  63. Mycopathologia. 1986 Oct;96(1):33-40 [PMID: 3540675]
  64. J Am Acad Dermatol. 1987 Jan;16(1 Pt 2):243-9 [PMID: 3546413]
  65. Mykosen. 1986 Dec;29(12):561-75 [PMID: 3547123]
  66. J Am Acad Dermatol. 1987 Aug;17(2 Pt 2):329-32 [PMID: 3305608]
  67. Antimicrob Agents Chemother. 2000 Jan;44(1):143-9 [PMID: 10602736]
  68. Clin Infect Dis. 2000 Jan;30(1):47-54 [PMID: 10619732]
  69. Ann Intern Med. 2000 Feb 1;132(3):205-8 [PMID: 10651601]
  70. Clin Infect Dis. 2000 Aug;31(2):545-53 [PMID: 10987719]
  71. Transpl Infect Dis. 1999 Sep;1(3):213-7 [PMID: 11428991]

MeSH Term

Adolescent
Adult
Aged
Child
Cryptococcosis
Female
Humans
Male
Middle Aged
Organ Transplantation
Time Factors

Word Cloud

Created with Highcharts 10.0.0neoformansinfectionorgantransplantclinicalrecipientspcharacteristicsvariablesinfluencingoutcomeCryptococcusCdeathreceivinglikelyinvolvementversus=0patientsbasedmayUniquewelldefinedreviewpublishedreportsfounddocumented28%overallrate42%typeprimaryimmunosuppressiveagentusedtransplantationinfluencedpredominantmanifestationcryptococcosisPatientstacrolimussignificantlylesscentralnervoussystem78%11%=0001skinsoft-tissueosteoarticular66%21%006nontacrolimus-immunosuppressionRenalfailureadmissionindependentlysignificantpredictoroddsratio16495%CI19-143004Hypothesesdataelucidatepathogenesisultimatelyguidemanagementrecipients:

Similar Articles

Cited By (109)